AbangeLabsNCPE’s perioperative pembrolizumab position shows the bottleneck: cost-effectiveness under uncertainty when indirect evidence informs decisions.
NCPE sets a conditional reimbursement path for perioperative pembrolizumab in resectable NSCLC
On 10 March 2026, the National Centre for Pharmacoeconomics recommended perioperative pembrolizumab in resectable high-risk NSCLC be considered for reimbursement if cost-effectiveness improves, citing strong direct trial evidence versus chemotherapy and uncertain indirect comparative estimates versus nivolumab-based care.